Xiaochen Hu1, Charlotte E Teunissen2, Annika Spottke3, Michael T Heneka4, Emrah Düzel5, Oliver Peters6, Siyao Li7, Josef Priller8, Katharina Buerger9, Stefan Teipel10, Christoph Laske11, Sander C J Verfaillie12, Frederik Barkhof13, Nina Coll-Padrós14, Lorena Rami14, Jose Luis Molinuevo15, Wiesje M van der Flier16, Frank Jessen17. 1. Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany. Electronic address: xiaochen.hu@uk-koeln.de. 2. Neurochemistry lab and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. 3. German Center for Neurodegenerative Disorder (DZNE), Bonn, Germany; Department of Neurology, University Hospital of Bonn, Bonn, Germany. 4. German Center for Neurodegenerative Disorder (DZNE), Bonn, Germany; Department of Neurodegeneration Diseases and Geriatric Psychiatry, University Hospital of Bonn, Bonn, Germany. 5. German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany; Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Magdeburg, Germany. 6. German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany; Department of Psychiatry, Charité Berlin, Berlin, Germany. 7. Department of Psychiatry, Charité Berlin, Berlin, Germany. 8. German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany; Department of Neuropsychiatry, Charité Berlin & Berlin Institute of Health, Berlin, Germany. 9. German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität LMU, Munich, Germany. 10. German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany; Department of Psychosomatic Medicine, University Hospital of Rostock, Rostock, Germany. 11. German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany; Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany. 12. Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. 13. Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands; Institutes of Neurology and Healthcare Engineering, University College London, London, United Kingdom. 14. Alzheimer's disease and other cognitive disorder Unit, Institut d'Investigacions Biomediques August Pi l Sunyer (IDIBAPS), Hospital Clinic, Barcelona, Spain. 15. Alzheimer's disease and other cognitive disorder Unit, Institut d'Investigacions Biomediques August Pi l Sunyer (IDIBAPS), Hospital Clinic, Barcelona, Spain; BarcelonaBeta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain. 16. Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. 17. Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany; German Center for Neurodegenerative Disorder (DZNE), Bonn, Germany.
Abstract
INTRODUCTION: Previous studies showed associations of brain volume differences and biomarker evidence for Alzheimer's disease (AD) in subjective cognitive decline (SCD). The consistency of this finding across SCD studies has not been investigated. METHODS: We studied gray matter volume differences between SCD subjects with and without cerebrospinal fluid biomarker evidence for AD across three European memory clinic samples (German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia study, Amsterdam, Barcelona). Analysis of covariance models with samples and cerebrospinal fluid biomarkers as between-subject factors were calculated. RESULTS: A significant main effect for AD biomarker (Aβ42- > Aβ42+) in the left medial temporal lobe (MTL) was found, with the absence of main effects for sample or interaction effects between AD biomarker and sample. This indicates consistent lower left MTL volume across three samples in SCD subjects with abnormal Aβ42 levels. DISCUSSION: Our results support the model that in the presence of AD pathology, SCD corresponds to the late preclinical stage (stage 2 of AD) with smaller MTL volumes.
INTRODUCTION: Previous studies showed associations of brain volume differences and biomarker evidence for Alzheimer's disease (AD) in subjective cognitive decline (SCD). The consistency of this finding across SCD studies has not been investigated. METHODS: We studied gray matter volume differences between SCD subjects with and without cerebrospinal fluid biomarker evidence for AD across three European memory clinic samples (German Center for Neurodegenerative Diseases Longitudinal Cognitive Impairment and Dementia study, Amsterdam, Barcelona). Analysis of covariance models with samples and cerebrospinal fluid biomarkers as between-subject factors were calculated. RESULTS: A significant main effect for AD biomarker (Aβ42- > Aβ42+) in the left medial temporal lobe (MTL) was found, with the absence of main effects for sample or interaction effects between AD biomarker and sample. This indicates consistent lower left MTL volume across three samples in SCD subjects with abnormal Aβ42 levels. DISCUSSION: Our results support the model that in the presence of AD pathology, SCD corresponds to the late preclinical stage (stage 2 of AD) with smaller MTL volumes.
Authors: Gonzalo Sánchez-Benavides; Gemma Salvadó; Eider M Arenaza-Urquijo; Oriol Grau-Rivera; Marc Suárez-Calvet; Marta Milà-Alomà; José María González-de-Echávarri; Carolina Minguillon; Marta Crous-Bou; Aida Niñerola-Baizán; Andrés Perissinotti; Juan Domingo Gispert; José Luis Molinuevo Journal: Alzheimers Dement (Amst) Date: 2020-11-11
Authors: Lauren Zajac; Bang-Bon Koo; Yorghos Tripodis; Asim Mian; Eric Steinberg; Jesse Mez; Michael L Alosco; Anna Cervantes-Arslanian; Robert Stern; Ronald Killiany Journal: Cereb Cortex Commun Date: 2020-05-28